TABLE 2.
Evaluation for therapeutic enhancement
| Disease | Xenograft | P (combination vs AZD1775) | P (combination vsirinotecan) | Therapeutic enhancement |
|---|---|---|---|---|
| Neuroblastoma | NB-1643 | <0.001 | <0.001 | Yes |
| Neuroblastoma | NB-Ebc1 | <0.001 | 0.009 | Yes |
| Neuroblastoma | NB-SD | <0.001 | 0.002 | Yes |
| Osteosarcoma | OS1 | <0.001 | <0.001 | Yes |
| Osteosarcoma | OS2 | <0.001 | <0.001 | Yes |
| Osteosarcoma | OS31 | <0.001 | <0.001 | Yes |
| Osteosarcoma | OS33 | <0.001 | <0.001 | Yes |
| Wilms tumor | KT-10 | <0.001 | 0.281 | No |
| Wilms tumor | KT-11 | <0.001 | 0.010 | Yes |
| Wilms tumor | KT-13 | 0.001 | <0.001 | Yes |
P values reflect differences in EFS between experimental groups and are tested using the Gehan-Wilcoxon test.